The CRISPR patent landscape in 2026 is a complex maze for biotech startups. This article dissects the current state, future implications, and strategic pathways for navigating intellectual property in gene editing.

This investor's guide unveils the top three gene editing technologies—CRISPR, Base Editing, and Prime Editing—poised for explosive growth by mid-2026, offering crucial insights for strategic biotech investment decisions.